Skip to main content
An official website of the United States government

Chemopreventive Agent Development

Designs, develops, implements, and monitors research on interventions that may block, reverse, or delay the early stages of cancer. Investigates nutrients, micronutrients, natural products, pharmacologic agents, biomolecules, and vaccines from preclinical to early-phase I clinical studies. Helps investigators to bridge the gaps between biology and identifying potential targets, and between discovery of targets and agents and clinical testing in people.

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

Major Programs

Staff List

Photo Name, Email, Phone Room Group(s)/Office
Asefa, Wosene
 wosene.asefa@nih.gov
240-276-6422 		5E504 Program Support Assistant | Chemopreventive Agent Development
Biswas, Kajal, Ph.D.
 kajal.biswas2@nih.gov
240-276-5614 		5E540 Program Officer | Chemopreventive Agent Development
Cholewa, Brian, Ph.D.
 brian.cholewa@nih.gov
240-276-7545 		5E446 Deputy Chief | Chemopreventive Agent Development
Clifford, John, Ph.D.
 john.clifford@nih.gov
202-235-4482 		5E430 Program Officer | Chemopreventive Agent Development
Gunasekharan, Vignesh, Ph.D.
 vignesh.gunasekharan@nih.gov
240-276-5814 		5E438 Program Officer | Chemopreventive Agent Development
Mohammed, Altaf, Ph.D.
 altaf.mohammed@nih.gov
240-276-6082 		5E542 Deputy Chief | Chemopreventive Agent Development
Nalli, Ancy, Ph.D., M.S.
 ancy.nalli@nih.gov
202-276-5265 		5E536 Program Officer | Chemopreventive Agent Development
Sei, Shizuko, M.D.
 shizuko.sei@nih.gov
240-276-5005 		5E452 Co-Chief | Chemopreventive Agent Development
Shoemaker, Robert, Ph.D.
 robert.shoemaker@nih.gov
240-276-7077 		5E454 Co-Chief | Chemopreventive Agent Development
Acting Chief | Nutritional Science
Vlad, Anda, M.D., Ph.D.
 anda.vlad@nih.gov
240-276-6422 		5E538 Program Officer | Chemopreventive Agent Development

Grants

PI Name PI Organization Title Grant Number Program Official
Dryden-Peterson, Scott

Brigham And Women'S Hospital
United States

 Botswana CASCADE Clinical Trials Site 3UG1CA275416-04S1 Maria Silvina Frech, Ph.D., M.S.
Duan, Bin

University Of Nebraska Medical Center
United States

 Flupirtine Analogue Synthesis and Screening for the Treatment of Chemotherapy-Induced Neuropathic Pain 1R21CA298918-01 Rachel Altshuler, Ph.D.
Duncavage, Eric J

Washington University
United States

 Whole Genome Sequencing for Genomic Evaluation and Risk Stratification of Patients with Myelodysplastic Syndromes 4UH3CA272904-02 Nicholas Hodges, Ph.D.
Duvall, Adam S.

University Of Chicago
United States

 Tailoring a fun and engaging tech-assisted cognitive behavioral therapy program for adolescents and young adults with hematological malignancies: A planning grant 1R34CA297498-01 Brennan Streck, Ph.D., RN, M.P.H.
Eastham, James A

Sloan-Kettering Inst Can Research
United States

 Influence of intra-individual variability in serial screening samples on clinical decision-making for risk stratification and biopsy by a single PSA and additional markers 5U01CA266535-04 Claire Zhu, Ph.D.
Eibl, Guido Erwin Michael

University Of California Los Angeles
United States

 Chemoprevention and mechanisms of obesity-promoted pancreatic adenocarcinoma 5P01CA236585-05
Eickhoff, Jens

University Of Wisconsin-Madison
United States

 CP-CTNet Coordinating Center 1UG1CA304955-01 Donald Johnsey
Eisenmann, Eric Daniel

Ohio State University
United States

 Damage-associated molecular patterns in chemotherapy toxicity 1R37CA299879-01 Rachel Altshuler, Ph.D.
El-Bayoumy, Karam E

Pennsylvania State Univ Hershey Med Ctr
United States

 Chemoprevention by Black Raspberry of Oral Cancer Induced by Tobacco Carcinogens: Translational Studies 5R01CA173465-10 Gabriela Riscuta, M.D., CNS
El-Serag, Hashem B

Baylor College Of Medicine
United States

 Prevention of Hepatocellular Carcinoma Related to Metabolic Syndrome 5P01CA263025-04 Asad Umar, D.V.M., Ph.D.
Eldridge, Ronald C

Emory University
United States

 Integrative Multi-Omics of Metabolomics and Epigenetics to Explore thePathophysiology of Cachexia and Survival in Head and Neck SquamousCell Carcinoma 1R03CA304028-01 Marjorie Perloff, M.D.
Elenitoba-Johnson, Kojo S. J.

Sloan-Kettering Inst Can Research
United States

 Genomic biomarkers of splenic lymphoma 5R01CA255655-06 Nicholas Hodges, Ph.D.
Elias, Kevin

Cleveland Clinic Lerner Com-Cwru
United States

 Ovarian cancer risk stratification using circulating miRNAs to assess BRCAness 7R03CA283252-02 Christos Patriotis, Ph.D., M.Sc.
Ellerton, John A

Southern Nevada Cancer Research Fdn
United States

 NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Required) 3UG1CA189829-11S1 Vanessa A. White, M.P.H.
Ellsworth, Grant B.

Weill Medical Coll Of Cornell Univ
United States

 Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico 3U54CA242639-06S3 Maria Silvina Frech, Ph.D., M.S.